MDS Clinical Supportive Criteria for Parkinson’s Disease are Associated with α-Synuclein Seed Amplification Assay Status
Objective: To assess the association between α-synuclein seed amplification assay (α-synuclein SAA) status with the supportive criteria of the MDS Clinical Diagnostic Criteria for Parkinson’s…Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain
Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…Melatonin Modulates NLRP3 Inflammasome Activation through TLR2 to Protect Against Parkinson’s Disease
Objective: This study aims to investigate the impact of MLT on inflammation signaling pathway mediated by TLR2 in α-synuclein (α-syn) overexpressed BV2 cells and PD…Investigating Copy Number Variations in SNCA and PRKN in a Cohort of Kazakhstani Patients with Parkinson’s Disease and Healthy Controls
Objective: To investigate the frequency of copy number variations (CNVs) in SNCA and PRKN in a cohort of Parkinson’s disease (PD) patients and healthy controls…Role of the Alpha-synuclein Seed Amplification Assay in Parkinson’s Disease Clinical Trials: A Case Report of Multiple System Atrophy Misdiagnosed as Parkinson’s Disease
Objective: Report a patient with Multiple System Atrophy (MSA) misdiagnosed as Parkinson’s disease (PD) and enrolled in a clinical trial for PD treatment with Mesenchymal…Concordance of Neuropathologic Diagnosis of Lewy Body Disease with Baseline Alpha-Synuclein Seed Amplification Assay in PPMI
Objective: To determine whether the alpha-synuclein seed amplification assay (aSyn-SAA) performed on cerebral spinal fluid (CSF) collected at the baseline (BL) PPMI visit is concordant…Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity
Objective: To evaluate the perceptivity of mTOR kinase activity inhibition for Parkinson's disease therapy (PD). Background: The protein kinase mTOR is currently considered as a…Immunoproteasome subunits as emerging contributors to neurodegeneration in Parkinson’s Disease
Objective: To gain comprehensive contribution of immunoproteasome in central nervous system of Parkinson's Disease Background: Recent investigations have elucidated that, in addition to the classical…Miniscope-based neural circuit profiling in freely behaving animals for preclinical therapeutic assessment
Objective: To advance translational research by revealing detailed relationships between neural circuit activity and behavioural symptoms in preclinical models Background: Conventional preclinical tests for CNS…Catalan MSA Registry (CMSAR): Applying new Clinical Criteria and Biomarkers for Increasing Diagnostic Accuracy, is New Better?
Objective: To reassess the CMSAR and determine if new criteria and new biomarkers can enhance diagnostic accuracy. Background: The CMSAR, conducted between 2015 and 2019,…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 51
- Next Page »